{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-22-000007","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.789175+00:00","generated_at":"2026-06-26T22:50:19.135556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252","bullets":["Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.","Revenue $30.1M in Q4 (up from $1.3M) due to Takeda collaboration revenue recognition; R&D expenses $16.2M.","Cash $268.8M as of Dec 31, 2021, sufficient into second half 2024.","Initial clinical data for SL-172154 in ovarian cancer showed favorable safety, target occupancy, and CD40 activation; combination trial planned.","SL-279252 showed anti-tumor activity including partial response in ocular melanoma; dose escalation continues to 24 mg/kg."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-22-000007","json":"https://secwatch.observer/filing/0001680367-22-000007.json","markdown":"https://secwatch.observer/filing/0001680367-22-000007.md","text":"https://secwatch.observer/filing/0001680367-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/0001680367-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/sttk-20220315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:50:19.135556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}